Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

vTv Therapeutics (VTVT) Enterprise Value (2016 - 2025)

vTv Therapeutics' Enterprise Value history spans 12 years, with the latest figure at -$88.9 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 155.98% year-over-year to -$88.9 million; the TTM value through Dec 2025 reached -$88.9 million, down 155.98%, while the annual FY2025 figure was -$88.9 million, 155.98% down from the prior year.
  • Enterprise Value for Q4 2025 was -$88.9 million at vTv Therapeutics, up from -$98.5 million in the prior quarter.
  • Across five years, Enterprise Value topped out at $54.1 million in Q1 2021 and bottomed at -$98.5 million in Q3 2025.
  • The 5-year median for Enterprise Value is -$625000.0 (2022), against an average of -$12.8 million.
  • The largest annual shift saw Enterprise Value surged 402.8% in 2023 before it crashed 6493.77% in 2024.
  • A 5-year view of Enterprise Value shows it stood at $11.4 million in 2021, then crashed by 61.23% to $4.4 million in 2022, then tumbled by 176.16% to -$3.4 million in 2023, then crashed by 927.49% to -$34.7 million in 2024, then crashed by 155.98% to -$88.9 million in 2025.
  • Per Business Quant, the three most recent readings for VTVT's Enterprise Value are -$88.9 million (Q4 2025), -$98.5 million (Q3 2025), and -$26.3 million (Q2 2025).